Recce Pharmaceuticals (ASX:RCE) Total Assets: A$2.04 Mil (As of Dec. 2025)


ASX:RCE Recce Pharmaceuticals Ltd ASX:RCE
31 GF Score
Price A$0.40
! 4 Warning Signs
View Full Analysis

What is Recce Pharmaceuticals Total Assets?

Recce Pharmaceuticals ASX:RCE -13.04% 31 Total Assets is A$2.04 Mil as of Dec. 2025. GuruFocus rates ASX:RCE with a GF Score™ of 31/100. The stock has 4 warning signs investors should review.

Recce Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2025 was A$2.04 Mil.

During the past 12 months, Recce Pharmaceuticals's average Total Assets Growth Rate was -25.90% per year. During the past 3 years, the average Total Assets Growth Rate was 23.50% per year. During the past 5 years, the average Total Assets Growth Rate was 29.20% per year.

During the past 10 years, Recce Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 58.60%. The lowest was 14.40%. And the median was 23.50%.

Total Assets is connected with ROA %. Recce Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2025 was -458.22%. Total Assets is also linked to Revenue through Asset Turnover. Recce Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2025 was 0.00.

Recce Pharmaceuticals  (ASX:RCE) Total Assets Explanation

Total Assets is connected with ROA %.

Recce Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2025 is

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=-33.12/( (12.414+2.042)/ 2 )
=-33.12/7.228
=-458.22 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Recce Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2025 is

Asset Turnover
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=0/( (12.414+2.042)/ 2 )
=0/7.228
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Recce Pharmaceuticals Total Assets Related Terms

Recce Pharmaceuticals Total Assets Historical Data

* Premium members only.

The historical data trend for Recce Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Recce Pharmaceuticals Total Assets Chart

Recce Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.68 12.62 2.60 6.62 12.41

Recce Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.47 6.62 4.21 12.41 2.04
ASX:RCE
31GF Score
Recce Pharmaceuticals Ltd ASX:RCE
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Recce Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Recce Pharmaceuticals's Total Assets for the fiscal year that ended in Jun. 2025 is calculated as

Total Assets=Total Equity (A: Jun. 2025 )+Total Liabilities (A: Jun. 2025 )
=-3.052+15.467
=12.42

Recce Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (Q: Dec. 2025 )+Total Liabilities (Q: Dec. 2025 )
=-18.618+20.659
=2.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of A$2.04 Mil mean?
Recce Pharmaceuticals (ASX:RCE) has a Total Assets of A$2.04 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Recce Pharmaceuticals and its competitors.
Is Recce Pharmaceuticals' Total Assets too high?
Recce Pharmaceuticals' current Total Assets is A$2.04 Mil. Overall, Recce Pharmaceuticals has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Recce Pharmaceuticals' Total Assets compare to VRTX and REGN?
Recce Pharmaceuticals' Total Assets of A$2.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Recce Pharmaceuticals and its competitors. Recce Pharmaceuticals's current Total Assets is A$2.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recce Pharmaceuticals stock overvalued right now?
Recce Pharmaceuticals (ASX:RCE) has a current Total Assets of A$2.04 Mil. The current Total Assets is A$2.04 Mil. Recce Pharmaceuticals' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Recce Pharmaceuticals (ASX:RCE), the current Total Assets is A$2.04 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Recce Pharmaceuticals Business Description

Other Exchanges R9Q:Germany
Address 3 Brodie Hall Drive, Suite 10, Technology Park, Bentley, WA, AUS, 6102
Recce Pharmaceuticals Ltd is an Australia-based, globally-focused biotechnology company that is pioneering the development and commercialisation of a drug discovery and development business commercialising new Classes of synthetic anti-infectives with broad-spectrum activity designed to address the urgent health threat of antibiotic-resistant superbugs and emerging viral pathogens. Its patented candidate, RECCE 327, has been developed for the treatment of life-threatening bacterial infections. It has one segment, which is the research and development of pharmaceutical drugs. Geographic segments are Australia, the UK, and the USA, of which the majority of the revenue comes from Australia. It offers antibiotic drugs to treat bacterial infections for Sepsis, Escherichia coli, and Others.
31GF Score

Get the complete analysis for ASX:RCE

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.40
Price